Catalyst Biosciences, Inc. announced two key additions to its clinical hemophilia programs with the appointments of Arwa Shurrab as vice president of regulatory affairs and Jamie Ellen Siegel, M.D., as the head of clinical development. Before joining Catalyst, Arwa was the director of regulatory affairs at Shire, where she served as a director leading the Hematology CMC team in the development of strategic plans and worldwide regulatory submissions. Jamie Ellen Siegel, M.D., brings to Catalyst over 30 years of clinical, clinical laboratory, and program development experience in the hematology field, particularly in hemophilia, with the last ten years in government and industry settings.